Product Description
Santa Ana’s SAB05 ADC program employs a novel technology for antibody-glucocorticoid conjugates. This approach allows the company to safely harness the long-established therapeutic efficacy of glucocorticoids while bypassing the collateral damage associated with the use of such drugs. (Sourced from: https://www.santaanabio.com/pipeline)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Antibody Drug Conjugate
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Santaana bio
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 0: Unknown
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|